LEXICON PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Defined Contribution Plan, Cost of $800.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-05
- LEXICON PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2025 was $800.00K, a 65.22% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2024 was $2.30M, a 91.67% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2023 was $1.20M, a 71.43% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2022 was $700.00K, a 75.00% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $800.00K 10-K · filed 2026-03-05 | |
| 2024-12-31 | $2.30M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $1.20M 10-K · filed 2026-03-05 | |
| 2022-12-31 | $700.00K 10-K · filed 2025-03-07 | |
| 2021-12-31 | $400.00K 10-K · filed 2024-03-25 | |
| 2020-12-31 | $900.00K 10-K · filed 2023-03-03 | |
| 2019-12-31 | $1.20M 10-K · filed 2022-03-10 | |
| 2018-12-31 | $1.00M 10-K · filed 2021-03-12 | |
| 2017-12-31 | $1.00M 10-K · filed 2020-03-12 | $1.03M 10-K · filed 2018-03-01 |
| 2016-12-31 | $700.00K 10-K · filed 2019-03-15 | $733.00K 10-K · filed 2017-03-06 |
| 2015-12-31 | $332.00K 10-K · filed 2018-03-01 | |
| 2014-12-31 | $376.00K 10-K · filed 2017-03-06 | |
| 2013-12-31 | $511.00K 10-K · filed 2016-03-11 | |
| 2012-12-31 | $490.00K 10-K · filed 2015-03-12 | |
| 2011-12-31 | $583.00K 10-K · filed 2014-03-07 | |
| 2010-12-31 | $642.00K 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |